Phase 1 Clinical Trial Planned to Evaluate DMT
Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”) recently announced that it was providing funding for a Phase 1 clinical trial aimed at evaluating the main psychotropic active ingredient dimethyltryptamine (“DMT”) found in ayahuasca. This clinical trial is slated to begin in the fourth quarter of this year. DMT occurs naturally and is the primary reason why the indigenous shamanic practitioners in the Amazon use ayahuasca in their ceremonies. However, DMT quickly triggers its psychoactive effects and these effects also wear off a lot sooner than those of other psychedelic ingredients like LSD and psilocybin. When DMT is administered as an…
